MX385679B - Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria. - Google Patents

Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.

Info

Publication number
MX385679B
MX385679B MX2017004664A MX2017004664A MX385679B MX 385679 B MX385679 B MX 385679B MX 2017004664 A MX2017004664 A MX 2017004664A MX 2017004664 A MX2017004664 A MX 2017004664A MX 385679 B MX385679 B MX 385679B
Authority
MX
Mexico
Prior art keywords
binding polypeptides
antigen
drug conjugates
antibody drug
glycoengineered antibody
Prior art date
Application number
MX2017004664A
Other languages
English (en)
Other versions
MX2017004664A (es
Inventor
Luis Z Avila
Qun Zhou
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2017004664A publication Critical patent/MX2017004664A/es
Publication of MX385679B publication Critical patent/MX385679B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2893—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a polipéptidos de unión (p. ej. anticuerpos) y conjugados de radicales de direccionamiento de los mismos que comprenden una unión con glicano modificado mediante ingeniería genética específico para el sitio dentro de glicanos nativos o modificados por ingeniería genética del polipéptido de unión. La presente descripción también proporciona ácidos nucleicos que codifican los polipéptidos de unión a antígeno, los vectores de expresión recombinantes y las células huésped para preparar tales polipéptidos de unión a antígeno. Asimismo se proporcionan los métodos de uso de los polipéptidos de unión a antígeno descritos en la presente invención para el tratamiento de enfermedades.
MX2017004664A 2014-10-09 2015-10-08 Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria. MX385679B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462061989P 2014-10-09 2014-10-09
PCT/US2015/054651 WO2016057769A2 (en) 2014-10-09 2015-10-08 Glycoengineered antibody drug conjugates

Publications (2)

Publication Number Publication Date
MX2017004664A MX2017004664A (es) 2017-06-30
MX385679B true MX385679B (es) 2025-03-18

Family

ID=54396949

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017004664A MX385679B (es) 2014-10-09 2015-10-08 Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
MX2021010354A MX2021010354A (es) 2014-10-09 2017-04-07 Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021010354A MX2021010354A (es) 2014-10-09 2017-04-07 Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.

Country Status (11)

Country Link
US (3) US10064952B2 (es)
EP (2) EP3204425B1 (es)
CN (2) CN113975406B (es)
AU (3) AU2015330869B2 (es)
CA (2) CA3205824A1 (es)
ES (1) ES2838680T3 (es)
MX (2) MX385679B (es)
PL (1) PL3204425T3 (es)
PT (1) PT3204425T (es)
SG (2) SG10202002153PA (es)
WO (1) WO2016057769A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY160126A (en) 2009-05-13 2017-02-28 Genzyme Corp Anti-human cd52 immunoglobulins
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
IL289918B2 (en) 2013-03-11 2025-07-01 Genzyme Corp Site-specific antibody-drug conjugation through glycoengineering
US10995148B2 (en) 2014-03-19 2021-05-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
PT3204425T (pt) * 2014-10-09 2020-12-18 Genzyme Corp Conjugados anticorpo fármaco glicomanipulados
US11684638B2 (en) * 2016-02-16 2023-06-27 Regents Of The University Of Minnesota Targeted delivery system, system components, and methods
US11135306B2 (en) * 2016-11-14 2021-10-05 CHO Pharma Inc. Antibody-drug conjugates
US20200299399A1 (en) * 2017-04-21 2020-09-24 Genzyme Corporation Treatment of Multiple Sclerosis with Anti-CD52 Antibodies
KR102110182B1 (ko) * 2017-09-20 2020-05-14 한양대학교 에리카산학협력단 신규한 옥심 유도체 화합물 및 이를 포함한 항체-약물 복합체
CN107501388A (zh) * 2017-09-22 2017-12-22 上海美吉医学检验有限公司 一种用于抗体‑分子定点偶联的方法及应用
US12485178B2 (en) 2018-04-09 2025-12-02 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
WO2019199634A1 (en) 2018-04-09 2019-10-17 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
US20230097887A1 (en) 2018-04-09 2023-03-30 Yale University Bi-functional Molecules to Degrade Circulating Proteins
US20220023434A1 (en) 2018-12-19 2022-01-27 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional Molecules for Lysosomal Targeting and Related Compositions and Methods
WO2020158943A1 (ja) 2019-02-01 2020-08-06 住友化学株式会社 抗体及びその機能性断片
US20210032285A1 (en) * 2019-03-11 2021-02-04 Cell Idx, Inc. Methods, compositions, and kits for trapping modified biomolecules
WO2020206063A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
EP4041313A4 (en) * 2019-10-10 2024-01-10 Yale University TECHNICAL ANTIBODIES AS MOLECULAR DEGRADERS THROUGH CELLULAR RECEPTORS
JP2023511756A (ja) 2020-01-31 2023-03-22 アヴィラー セラピューティクス インコーポレイテッド 細胞外タンパク質を分解するａｓｇｐｒ結合性化合物
CA3210709A1 (en) * 2021-03-23 2022-09-29 Glycoera Ag Glycan-mediated protein degradation
WO2022235699A2 (en) 2021-05-03 2022-11-10 Avilar Therapeutics, Inc. Potent asgpr-binding compounds for the degradation of immunoglobulins and other proteins
CA3226268A1 (en) 2021-07-14 2023-01-19 Lycia Therapeutics, Inc. M6pr cell surface receptor binding compounds and conjugates
JP2024524614A (ja) 2021-07-14 2024-07-05 ライシア セラピューティクス， インコーポレイテッド Ａｓｇｐｒ細胞表面受容体結合化合物及びコンジュゲート
MX2024005342A (es) * 2021-11-03 2024-09-27 Adcentrx Therapeutics Inc Análogos de auristatina novedosos e inmunoconjugados de estos.
CN118829645A (zh) * 2021-12-23 2024-10-22 艾德森特克斯治疗股份有限公司 新型澳瑞他汀类似物及其免疫偶联物
EP4651903A1 (en) 2023-01-18 2025-11-26 Lycia Therapeutics, Inc. M6pr binding compounds and conjugates
EP4651901A1 (en) 2023-01-18 2025-11-26 Lycia Therapeutics, Inc. Cycling lysosomal targeting antibody conjugates
KR20250144397A (ko) 2023-01-18 2025-10-10 리시아 테라퓨틱스, 인크. Asgpr 결합 화합물 및 접합체
CN120835793A (zh) 2023-01-18 2025-10-24 利西亚治疗公司 用于降解自身抗体的溶酶体靶向双功能分子
WO2025035040A1 (en) 2023-08-09 2025-02-13 Lycia Therapeutics, Inc. Lysosomal targeting bifunctional molecules for degradation of muscle-specific kinase autoantibodies
WO2025088546A1 (en) 2023-10-25 2025-05-01 Ablynx N.V. Fc domain variants with enhanced fc receptor binding
WO2026015664A1 (en) 2024-07-10 2026-01-15 Lycia Therapeutics, Inc. Cycling lysosomal targeting chimeras targeting immunoglobulin e (ige)

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
DE68928427T2 (de) 1988-09-15 1998-06-04 Univ Columbia Antikörper mit modifiziertem Kohlenhydratgehalt und Verfahren zur Herstellung und Verwendung
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
CA2018248A1 (en) 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
ATE208633T1 (de) 1994-09-16 2001-11-15 Merck Patent Gmbh Immunokonjugate
GB9422383D0 (en) 1994-11-05 1995-01-04 Wellcome Found Antibodies
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1996040662A2 (en) 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
SE9601245D0 (sv) 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
WO1998005787A1 (en) 1996-08-02 1998-02-12 Bristol-Myers Squibb Company A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6953675B2 (en) 1997-11-06 2005-10-11 Immunomedics, Inc. Landscaped antibodies and antibody fragments for clinical use
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US20020142374A1 (en) 1998-08-17 2002-10-03 Michael Gallo Generation of modified molecules with increased serum half-lives
AU6059699A (en) 1998-09-23 2000-04-10 Regents Of The University Of California, The Synthetic peptides, conjugation reagents and methods
EP1006183A1 (en) 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
AU2001270609A1 (en) 2000-06-30 2002-01-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20050107595A1 (en) 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2305312B1 (en) * 2001-10-10 2015-03-04 ratiopharm GmbH Remodelling and glycoconjugation of follicle-stimulating hormone (FSH)
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
CA2478011C (en) 2002-03-01 2013-05-21 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
WO2004029207A2 (en) 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
CN107213469A (zh) 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
EP1706424B1 (en) 2004-01-12 2009-07-22 Applied Molecular Evolution, Inc. Fc region variants
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
EP1745141B2 (en) 2004-05-04 2019-09-25 Novo Nordisk Health Care AG O-linked glycoforms of faktor vii and method to manufacture them
WO2006085967A2 (en) 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
EP1853634B1 (en) * 2005-02-23 2016-08-10 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
WO2006105021A2 (en) 2005-03-25 2006-10-05 Tolerrx, Inc. Gitr binding molecules and uses therefor
EP1871808A2 (en) 2005-03-31 2008-01-02 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
JP2008537941A (ja) 2005-03-31 2008-10-02 ゼンコー・インコーポレイテッド 最適化特性を有するＦｃ変異体
US8163881B2 (en) 2005-05-31 2012-04-24 The Board Of Regents Of The University Of Texas System Immunoglobulin molecules with improved characteristics
JP2009504569A (ja) 2005-06-30 2009-02-05 セントカー・インコーポレーテツド 向上した治療活性をもつ方法および組成物
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
CA2655903A1 (en) 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
US8460362B2 (en) 2006-07-20 2013-06-11 Orbusneich Medical, Inc. Bioabsorbable polymeric medical device
CA2665480C (en) * 2006-10-04 2019-11-12 Novo Nordisk A/S Glycerol linked pegylated sugars and glycopeptides
FI20060946A0 (fi) 2006-10-26 2006-10-26 Glykos Finland Oy Influenssaviruksen nukleiinihappoja ja peptidejä
ES2464815T3 (es) 2007-01-09 2014-06-04 Biogen Idec Ma Inc. Anticuerpos SP35 y usos de éstos
AR066476A1 (es) 2007-05-08 2009-08-19 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugaods de anticuerpos y farmacos
WO2009045894A1 (en) 2007-09-28 2009-04-09 Centocor, Inc. Methods and structural conformations of antibody preparations with increased resistance to proteases
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
CA2698541C (en) 2007-10-19 2018-01-09 Genentech, Inc. Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
ES2643239T3 (es) 2008-01-31 2017-11-21 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
UA40611U (ru) 2008-05-26 2009-04-27 Владимир Семенович Живченко Способ десульфурации железоуглеродистого расплава в тигельной печи
WO2010027797A1 (en) 2008-08-26 2010-03-11 Macrogenics Inc. T-cell receptor antibodies and methods of use thereof
EP2233499A1 (en) 2009-03-26 2010-09-29 CSL Behring AG Antibody composition with altered Fab sialylation
JP5826772B2 (ja) * 2010-02-16 2015-12-02 ノヴォ ノルディスク アー／エス コンジュゲートタンパク質
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
BR112013003095B1 (pt) 2010-08-10 2023-03-28 Glycotope Gmbh Método para controle da meia-vida em circulação de um anticorpo ou um fragmento ou derivado funcional do mesmo, composições de anticorpo, seu usos e seus métodos de produção
TWI588156B (zh) 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
SI2895513T1 (sl) * 2012-09-12 2018-11-30 Genzyme Corporation Polipeptidi, ki vsebujejo FC, s spremenjeno glikozilacijo in zmanjšano efektorsko funkcijo
IL289918B2 (en) * 2013-03-11 2025-07-01 Genzyme Corp Site-specific antibody-drug conjugation through glycoengineering
US10995148B2 (en) 2014-03-19 2021-05-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
WO2015157446A1 (en) * 2014-04-08 2015-10-15 University Of Georgia Research Foundation Inc. Site-specific antibody-drug glycoconjugates and methods
PT3204425T (pt) * 2014-10-09 2020-12-18 Genzyme Corp Conjugados anticorpo fármaco glicomanipulados

Also Published As

Publication number Publication date
PT3204425T (pt) 2020-12-18
CN108025083B (zh) 2021-09-03
US20190060481A1 (en) 2019-02-28
US20160136299A1 (en) 2016-05-19
EP3204425A2 (en) 2017-08-16
CN108025083A (zh) 2018-05-11
CA2964123A1 (en) 2016-04-14
CN113975406A (zh) 2022-01-28
SG10202002153PA (en) 2020-05-28
US20220088214A1 (en) 2022-03-24
MX2021010354A (es) 2021-10-01
MX2017004664A (es) 2017-06-30
CN113975406B (zh) 2024-11-22
US10064952B2 (en) 2018-09-04
SG11201702786RA (en) 2017-05-30
AU2021245177B2 (en) 2025-02-27
AU2021245177A1 (en) 2021-11-04
CA2964123C (en) 2023-09-05
WO2016057769A3 (en) 2016-06-02
PL3204425T3 (pl) 2021-03-08
WO2016057769A2 (en) 2016-04-14
CA3205824A1 (en) 2016-04-14
AU2015330869A1 (en) 2017-05-25
EP3799887A1 (en) 2021-04-07
EP3204425B1 (en) 2020-09-16
US11160874B2 (en) 2021-11-02
AU2025203385A1 (en) 2025-05-29
AU2015330869B2 (en) 2021-07-08
ES2838680T3 (es) 2021-07-02

Similar Documents

Publication Publication Date Title
MX385679B (es) Conjugados de farmacos de anticuerpos modificados mediante glicoingenieria.
MX384991B (es) Glucomodificación de restos de direccionamiento específica del sitio.
MX370356B (es) Conjugacion de anticuerpo-farmaco especifica de sitio mediante glicoingenieria.
CL2020000039A1 (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes. (divisional solicitud 201700647)
MX2017017145A (es) Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra cancer de ovario y otros canceres.
CO2018005436A2 (es) Anticuerpos y fragmentos de anticuerpo para la conjugación sitio-específica
MX2018004140A (es) Peptidos y combinacion de peptidos para usarse en la inmunoterapia contra el cancer pulmonar microcelular y otros tipos de cancer.
MX395287B (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
MX2021013147A (es) Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra cancer de ovario y otros canceres.
MX2017012427A (es) Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra diferentes tumores.
MX2020004741A (es) Nuevos receptores de las celulas t modificados geneticamente y terapias immunologicas que emplean los mismos.
BR112018012352A2 (pt) anticorpos anti-lag3 e fragmentos de ligação ao antígeno
MX2017006866A (es) Pares de unión para producción de péptidos.
CO2017003212A2 (es) Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de tnf
EA202091166A1 (ru) ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
AR105444A1 (es) Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3)
MX2017017148A (es) Peptidos novedosos y combinacion de peptidos para usarse en la inmunoterapia contra cancer esofagico y otros canceres.
EA201891420A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
EA201990017A1 (ru) Антитела к миостатину и способы их применения
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
BR112018075032A2 (pt) proteínas de hemaglutinina do vírus influenza e seus uso
BR112018075644A2 (pt) anticorpos anti-cd98 e conjugados de anticorpo e fármaco
MX2022000222A (es) Vectores virales recombinantes que contienen la proteina menor del virus del sindrome reproductor y respiratorio porcino (prrsv) y sus metodos de elaboracion y uso.
CL2021002168A1 (es) Péptido asociado a tumor; ácido nucleico; vector de expresión; célula huésped recombinante; método para producir el péptido; linfocitos t activados y su método de producción; anticuerpo; tcr; uso para tratar el cáncer; kit y composición farmacéutica; método para producir vacuna; y áptaro (divisional solicitud no. 201702407).
BR112017001463A2 (pt) célula hospedeira melhorada para produzir proteínas